



ASX ANNOUNCEMENT

5 JUNE 2024

PHASE 1B ADVENT-AML TRIAL OF CHM CORE-NK ADVANCES TO NEXT COHORT

- ADVENT-AML is the first trial to evaluate the synergy of NK cell therapy in combination with the current standard of care for acute myeloid leukemia (AML)
- Three patients were treated in first cohort; none experienced dose-limiting toxicities
- Second cohort now open to enrolment, testing higher dose of CHM CORE-NK

Sydney, Australia, 5 June 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce that the Phase 1B ADVENT-AML trial of CHM CORE-NK has advanced to the next planned cohort.

The ADVENT-AML (NCT05834244) Phase 1B clinical trial is an investigator-initiated trial currently open to enrollment at The University of Texas MD Anderson Cancer Center under Principal Investigator Abhishek Maiti MD, Assistant Professor in the Department of Leukemia. This is the first trial to evaluate the synergy of NK cell therapy in combination with the current standard of care for AML, Azacitidine and Venetoclax (aza/ven).

In the first cohort, which opened to enrolment in Q1 2024, three subjects with relapsed or refractory AML received CHM CORE-NK at Dose Level 1, in combination with standard-of-care aza/ven. No dose-limiting toxicities (DLTs) were reported during the 28-day DLT evaluation period.

Following review of the data from the first three patients, the safety monitoring committee has authorized the trial to advance to the next cohort, in which three subjects with relapsed or refractory AML will receive CHM CORE-NK at Dose Level 2 in combination with aza/ven. The study is designed to then enrol up to 20 subjects with newly diagnosed AML who are not eligible for intensive chemotherapy or allogeneic stem cell transplant.

“It has been great to see the progress of this clinical trial for these AML patients” said Dr Rebecca McQualter, Chief Operating Officer of Chimeric.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease



progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 current clinical programs and plans to open additional clinical programs in 2024.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CDH17 CAR T was published in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer. CDH17 CAR T is currently in preclinical development with a planned phase 1A clinical trial in gastrointestinal and neuroendocrine tumours in 2024.

CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours and is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated, universal off-the-shelf NK cell therapy manufactured with the CORE-NK platform, which can produce hundreds of doses of activated NK cells in a single manufacturing run. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors

Dr Rebecca McQualter
Chief Operating Officer
Chimeric Therapeutics
T: + 61 498 966 180
E: RMcQualter@chimerictherapeutics.com
W: www.chimerictherapeutics.com



Media

Matthew Wright

NWR Communications

P: +61 451 896 420

E: matt@nwrcommunications.com.au